An expanded biomarker panel for the detection of prostate cancer from urine DNA

BACKGROUND: Prostate cancer diagnosis using the PSA test remains controversial because of overdiagnosis and overtreatment of potentially indolent cancers. There remains a need to increase the diagnostic lead time and to target treatment to patients with significant disease. One possible approach to...

Descripción completa

Detalles Bibliográficos
Autores principales: Brikun, Igor, Nusskern, Deborah, Freije, Diha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598372/
https://www.ncbi.nlm.nih.gov/pubmed/31297302
http://dx.doi.org/10.1186/s40164-019-0137-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598372/
https://www.ncbi.nlm.nih.gov/pubmed/31297302
http://dx.doi.org/10.1186/s40164-019-0137-x

Ejemplares similares